The immune system constantly patrols the body for abnormal cells, including cancer cells. Among its most powerful weapons are CD8-positive cytotoxic T cells, which recognize tumor-associated signals and can directly destroy malignant cells. Gastric tumors, however, often create an immunosuppressive environment that prevents these lymphocytes from functioning properly. Immune checkpoint inhibitors, or ICIs, are designed to release some of the molecular brakes placed on T cells, but their success depends heavily on the signals already operating inside the tumor.

D-serine belongs to a group of molecules known as D-amino acids. Most amino acids used to build proteins in humans are L-amino acids, while D-amino acids are their mirror-image forms, or enantiomers. Although D-amino acids were once considered biologically insignificant, scientists now know that they can occur naturally in body fluids and may originate from food, intestinal microbes, or cellular metabolism. D-serine is already recognized for its role in nervous-system signaling, but the Keio team investigated whether it could also influence cancer immunity.

The researchers used mouse models of gastric cancer and introduced different D-amino acids and their corresponding L-amino acids into tumors. Among the compounds tested, only D-serine produced a clear increase in tumor growth compared with untreated controls. Detailed analysis showed that the molecule was not simply feeding the cancer cells. Instead, it altered the immune ecosystem surrounding the tumors, increasing the abundance and activity of anti-inflammatory immune cells, especially M2-like macrophages.

Macrophages are highly adaptable immune cells that can either attack tumors or support their growth, depending on the chemical signals around them. In the D-serine-treated tumors, macrophages acquired a tumor-promoting, immunosuppressive profile. At the same time, the number of CD8-positive cytotoxic T cells fell, and the T cells that remained showed markedly reduced activity. This combination—more suppressive macrophages and fewer functional killer T cells—created conditions that allowed gastric tumors to expand with less immune resistance.

The team then examined the molecular secretions of tumor-associated macrophages, commonly called TAMs. In tumors exposed to D-serine, these cells released unusually high amounts of fibronectin 1, or FN1, and secreted phosphoprotein 1, known as SPP1 or osteopontin. Both molecules have been associated with immune regulation and tumor progression. In this setting, they appeared to contribute to the suppression of CD8-positive T cells, helping the tumor maintain an immune-protected niche.

One experiment provided evidence that SPP1 was an important part of this pathway. When the researchers administered antibodies designed to neutralize SPP1 in D-serine-enhanced tumors, tumor growth slowed and approached the rate observed in mice with lower D-serine activity. The result suggests that D-serine may operate upstream of a signaling cascade in which macrophages release SPP1 and FN1, ultimately weakening the T-cell response. However, the findings do not yet establish that blocking SPP1 or D-serine will be effective as a treatment in people.

To investigate whether the mouse findings might have clinical relevance, the researchers analyzed patient data from several human cohorts. Patients with gastric cancer had higher serum D-serine concentrations than healthy controls. The highest levels were detected in people with stage IV disease whose tumors had resisted ICI treatment. This association raises the possibility that a blood test for D-serine could help identify patients whose tumors are more likely to evade immunotherapy, although larger prospective studies will be needed before such testing can guide clinical decisions.

The findings are particularly significant because ICIs are increasingly used as first-line treatment for advanced gastric cancer, yet responses vary widely and treatment can cause immune-related adverse events. Measuring D-serine in blood, and potentially in stool, could offer a way to assess the tumor’s immunological state before therapy begins. The researchers are now examining whether D-serine levels can predict treatment response and whether intestinal bacteria responsible for producing the molecule contribute to its accumulation. If future studies confirm the mechanism, therapies aimed at reducing D-serine or interrupting its downstream signals could provide a new strategy for restoring anti-tumor immunity. For now, the work identifies D-serine as a promising biomarker and a potential immune-regulatory target, but its therapeutic value remains to be tested in human clinical trials.

Subject of Research: Animals

Article Title: D-serine as a metabolic immune checkpoint in the tumour microenvironment

News Publication Date: 31-Jul-2026

Web References: https://doi.org/10.1016/j.ebiom.2026.106402; https://www.keio-sujino-lab.com/; https://researchmap.jp/tsujino

References: https://doi.org/10.1016/j.ebiom.2026.106402

Image Credits: Shohei Suzuki and Tomohisa Sujino, Keio University, Japan

Keywords: D-serine, gastric cancer, tumor immunity, immune checkpoint inhibitors, immunotherapy resistance, tumor-associated macrophages, CD8-positive T cells, SPP1, FN1, metabolic immune checkpoint

Merlin, encoded by the NF2 tumor suppressor gene, has been largely studied in nervous system tumors, but its role in breast cancer has remained relatively unexplored—until now. The research team used advanced molecular and cellular assays to delineate how the loss of Merlin disrupts tumor-immune interactions. Their findings indicate that Merlin deficiency triggers a cascade of immunomodulatory changes contributing to an immune microenvironment less capable of mounting an effective anti-tumor response.

Mechanistically, the absence of functional Merlin appears to encourage the upregulation of specific immune checkpoint molecules and the secretion of cytokines that recruit and activate immunosuppressive cell types. These immune cells, including regulatory T cells and myeloid-derived suppressor cells, create a protective niche for breast tumor cells, effectively shielding them from immune attack. This immunosuppressive milieu not only facilitates tumor survival but could also underlie resistance to conventional immunotherapies.

The study employed sophisticated in vitro and in vivo models to convincingly link Merlin loss with increased tumor aggressiveness and immune evasion. Importantly, reconstitution of Merlin expression reinstated immune sensitivity, highlighting a potential therapeutic avenue. Targeting pathways downstream of Merlin or combining checkpoint blockade with strategies to restore Merlin function might reinvigorate anti-tumor immunity in resistant breast cancers.

These discoveries hold significant clinical implications. Breast cancer remains one of the leading causes of cancer mortality worldwide, and immune evasion is a hallmark of treatment failure. Understanding the molecular determinants that tip the immune balance towards suppression is vital for developing next-generation immunotherapies. Merlin’s role as a central modulator underscores the complexity of tumor-immune dynamics and offers a novel biomarker for patient stratification.

Further exploration is warranted to map out the precise signaling networks and to evaluate whether Merlin deficiency correlates with specific breast cancer subtypes or clinical outcomes. Additionally, integrating Merlin status into existing immunotherapeutic regimens could optimize efficacy and minimize therapeutic resistance.

This study not only deepens our comprehension of breast cancer biology but also propels the field toward more personalized and mechanistically informed treatments. By revealing how the loss of a single tumor suppressor reprograms the immune landscape, it opens exciting avenues for research and therapeutic innovation.

As investigations continue, Merlin emerges not merely as a tumor suppressor but as a pivotal immune modulator, highlighting the intertwined fate of cancer progression and immune regulation.

Subject of Research: The role of Merlin deficiency in shaping the immunosuppressive environment of breast cancer.

Article Title: Merlin deficiency supports an immunosuppressive milieu in breast cancer.

Article References:
Elbahoty, M.H., Metge, B.J., Elhamamsy, A.R. et al. Merlin deficiency supports an immunosuppressive milieu in breast cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03223-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03223-7

Epigenetic regulation, through post-translational modifications of histone residues, orchestrates chromatin dynamics and gene expression profiles essential for cellular identity and homeostasis. LSD1 operates as a histone demethylase that selectively removes methyl groups from histone H3 at lysine 4 (H3K4) and lysine 9 (H3K9), modulating transcriptional programs that can either activate or repress gene expression. The study reveals that in early-stage OSCC, aberrant upregulation of LSD1 activity sustains oncogenic signaling cascades, notably via altering phosphorylation states of cyclin-dependent kinase 7 (CDK7), a pivotal factor in cell cycle progression and transcriptional regulation. By orchestrating CDK7 phosphorylation, LSD1 indirectly sustains the activation of Signal Transducer and Activator of Transcription 3 (STAT3), a well-known promoter of oncogenesis and immune evasion.

Using a combination of sophisticated genetic knockout models and pharmacological inhibition with specific LSD1 inhibitors such as SP2509, the research team demonstrated a notable suppression of OSCC preneoplastic progression. These interventions not only halted cellular proliferation but also induced a profound remodeling of the tumor microenvironment that favored anti-tumor immune responses. Most strikingly, LSD1 inhibition alleviated immunosuppressive barriers by downregulating CTLA4, a key checkpoint molecule that hinders CD8+ T cell function. The resulting augmented infiltration and activation of cytotoxic T lymphocytes underscore a dual mechanism whereby LSD1 inhibition simultaneously disrupts oncogenic signaling and reactivates host immunity.

The translational significance of these findings was further reinforced through a pioneering veterinary clinical trial employing Seclidemstat—a clinical stage LSD1 inhibitor—establishing both safety and efficacy in feline models of OSCC. Seclidemstat effectively suppressed STAT3 phosphorylation and mitigated tumor growth while amplifying immune cell infiltration. This trial provides critical proof-of-concept evidence that targeting LSD1 in early-stage oral preneoplasia is a viable therapeutic strategy and bridges preclinical findings with potential clinical applications.

Drilling deeper into the molecular underpinnings, the research delineates how LSD1-mediated histone demethylation tunes CDK7 activity via site-specific phosphorylation events. CDK7, as a component of the transcription factor TFIIH, participates in the phosphorylation of the RNA polymerase II C-terminal domain, thereby influencing global transcriptional elongation. The dysregulation of CDK7 in the context of enhanced LSD1 activity thus facilitates persistent STAT3 activation, fostering an environment conducive to epithelial transformation and immunosuppression. This novel axis connecting LSD1, CDK7 phosphorylation, and STAT3 signaling advances our mechanistic understanding of OSCC preneoplasia and identifies multiple nodal points for therapeutic intervention.

Immune evasion remains a hallmark of cancer progression, and the revelation that LSD1 inhibition diminishes CTLA4-mediated immunosuppression marks a significant milestone in the modulation of tumor-immune dynamics. The restoration of CD8+ T cell infiltration and effector functions upon LSD1 blockade suggests that epigenetic regulators critically modulate the immunological landscape of early OSCC lesions. By relieving the immune checkpoint constraints and invigorating anti-tumor immunity, LSD1 inhibitors present an appealing complementary approach to existing immunotherapies, potentially overcoming resistance mechanisms inherent in OSCC.

Furthermore, the study challenges the conventional paradigm that treats OSCC predominantly at invasive stages. The ability to intercept tumorigenesis at its preneoplastic inception by modulating epigenetic readers and writers portends a paradigm shift in oral oncology. Early therapeutic intervention leveraging LSD1 inhibitors could drastically reduce OSCC incidence and improve long-term survival, circumventing the morbidity associated with advanced disease and exhaustive treatments.

This investigation also propels the field of cancer epigenetics forward, emphasizing the nuanced roles of demethylases such as LSD1 in tumor progression outside of classical genetic mutations. Integrating epigenetic modulation with immune reactivation offers a multipronged strategy to disrupt the complex crosstalk between cancer cells and their microenvironment. The potential to combine LSD1 inhibitors with immune checkpoint blockade or other targeted agents opens exciting avenues for combination therapies aimed at durable tumor suppression.

Given the compelling evidence in both murine and feline models, future clinical trials in humans are poised to validate LSD1 inhibition as a cornerstone in early OSCC management. The ongoing development of potent, selective LSD1 inhibitors with favorable pharmacokinetic profiles will be critical to translating these findings into effective therapies. Moreover, identifying reliable biomarkers to stratify patients most likely to benefit from such interventions will optimize clinical outcomes.

Dr. Manish Bais and his team underscored the importance of this discovery by emphasizing how targeting the epigenetic machinery is not merely about halting tumor cell proliferation but also about restoring the intricate balance of immune surveillance that cancer subverts. The dual action of stopping tumor progression and reawakening effective anti-tumor immunity represents a sophisticated therapeutic advance that harnesses the body’s natural defenses in combating early oral cancer.

In conclusion, the elucidation of LSD1’s role in OSCC preneoplasia via modulation of CDK7 phosphorylation and STAT3 signaling, along with its impact on immunosuppression, presents a transformative understanding of oral carcinogenesis. The validation of LSD1 inhibitors like SP2509 and Seclidemstat as promising agents to reverse early neoplastic changes and boost anti-tumor immunity heralds a new era in precision oncology. Targeting the epigenetic control points in combination with immunomodulation may redefine OSCC prevention and treatment strategies, offering renewed hope to patients at risk of this devastating disease.

Subject of Research: Not applicable
Article Title: Lysine-specific demethylase 1 controls key OSCC preneoplasia inducer STAT3 through CDK7 phosphorylation during oncogenic progression and immunosuppression
News Publication Date: 17-Apr-2025
Web References: http://dx.doi.org/10.1038/s41368-025-00363-x
References: 10.1038/s41368-025-00363-x
Image Credits: international journal of oral science
Keywords: Oral cancer